Week in Review: China Investors Announce $4 Billion of Life Science Deals

Temasek of Singapore invested $800 million in Verily Life Sciences of San Francisco, the health sciences spin-out of Google's R&D operations; WuXi Biologics, the biologics arm of WuXi AppTec, filed to conduct its much-anticipated IPO on the Hong Kong Exchange; Sanpower Group enlisted China's CITIC Bank to raise $2.9 billion for a healthcare M&A fund for Sanpower's healthcare acquisitions; Beijing Mabworks, a gene engineering mAb company, raised $39 million in a Series B round led by Shenzhen GTJA Investment; Guangzhou Wondfo Biotech participated in a $35 million Series D funding of UK diagnostic maker Atlas Genetics; Suzhou Connect raised a total of $25 million to develop drugs that target autoimmune diseases and cancer; Shandong Yaohua Medical in-licensed China rights to the LuViva® Advanced Cervical Scan from Guided Therapeutics; Jiangsu Nhwa Pharma in-licensed China rights to a clinical stage oxygen treatment from NuvOx Pharma of Tuscon, Arizona; BeiGene started a global Phase III trial of its lead molecule, BGB-3111, a Bruton's tyrosine kinase (BTK) inhibitor; Neovia Oncology, a Seattle JV owned by Seattle's ANU and PUMC Pharma of Beijing, enrolled its first patient in a Phase I trial of a novel drug that increases immunotherapy response in cancer patients; and China instituted a "Two-Invoice" system for drug distribution to public hospitals, which is expected to drive retail drug prices lower and will increase pressure to roll-up distribution networks. More details.... Stock Symbols: (SHZ: 300482) (OTCQB: GTHP) (NSDQ: BGNE) Share this with colleagues: // //